A plaque or tartar claim needs evidence for the finished product and intended use. A fresh-breath description, an ingredient paper and a VOHC listing for another product answer different questions.
Start with the exact product and endpoint
Ask the supplier which finished formula was studied, in which species and under which directions. Plaque and calculus are separate endpoints; a result for one should not quietly become a claim for both. Match the study product code to the current specification and retain the connection in the claim file. If the evidence concerns an ingredient, identify the missing steps between that ingredient and the proposed oral film. The amount delivered, route of use and contact conditions may differ. A marketing name is not enough to establish equivalence. Before commissioning new work, ask the study team to define the endpoint and the proposed claim together. That conversation prevents a brand from collecting a result that cannot support the wording already planned for its carton.
Read the numerical benchmark in context
VOHC’s published trial requirements specify a minimum 15% reduction in plaque or tartar scores in each of two trials, a minimum mean reduction of 20% across the two, and a statistically significant difference in each trial for the stated test-versus-negative-control comparison. The protocol also distinguishes products with different mechanisms and control requirements. These are VOHC submission criteria, not a universal legal threshold for every dental product claim. A supplier cannot infer acceptance from a percentage alone. For a proposed film, discuss the appropriate protocol with VOHC before treating another product format’s design as applicable. Review the actual study report for the comparator, scoring method and tested directions. Keep the numerical outcome connected to those conditions when deciding whether a claim can be used. VOHC: trial protocol requirements.
Verify a seal and retain the evidence file
The public VOHC accepted-products directory identifies products and whether the accepted claim concerns plaque, tartar or both. Check the exact name, species and listed claim; a company’s other accepted products do not establish acceptance for a new private label film. Do not place a seal on artwork without the applicable permission. The claim file should also retain the report version, approved wording and any conditions imposed by the study or acceptance process. When a formula, size or use instruction changes, review whether the original evidence still covers it. This article does not claim VOHC acceptance for HYTANBIO pet oral films. Buyers developing dental concepts should treat evidence review as a separate project requirement, alongside formulation feasibility and the destination market’s labeling review. VOHC: accepted products.
Buyer checklist
- Match the studied formula and species to the proposed product.
- Separate plaque, tartar and breath endpoints.
- Request the full report, comparator and statistical analysis.
- Verify any seal against the exact product listing and permitted use.
- Reassess evidence when the formulation or directions change.
Questions buyers ask
Does fresh breath prove plaque reduction?
No. Breath and plaque are different outcomes. A claim file should contain evidence for the endpoint stated on the label.
Can an ingredient study support a finished oral film claim by itself?
It supplies background, but the connection to the finished formula, use conditions and intended species must be justified. Do not imply a finished-product trial occurred when it did not.
Does meeting a percentage automatically grant a VOHC seal?
No. VOHC reviews submissions under its requirements and authorizes accepted use. A numerical result alone is not permission to display the seal.
References and scope
Sources checked on 23 October 2026. This is supplier-authored development guidance, not an independent clinical review. Calculations marked as examples are not product test results. Questions or corrections: info@hytanbio.com.